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requirement in France; continuous monitoring will be needed to better understand 
positive and negative drivers of decisions.
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Consumer Interest In AdoPtIng An eleCtronIC HeAltH reCord (eHr) 
mobIle APPlICAtIon bAsed on tHe rIsk tHAt IdentIfIAble InformAtIon 
Is leAked
Wasserman D, Claeys C, Radley C, Tomaszewski K
KJT Group, Inc., Honeoye Falls, NY, USA
Objectives: This study was designed to understand consumer interest in a mobile 
application designed to allow individuals to view their personal health record on a 
mobile device, and to share their health records with someone else if they choose. 
As a secondary objective, this study evaluated the likelihood of consumers to use 
the device based on the varying risk of a leak of their identifiable information (risk 
tolerance). MethOds: A representative (U.S.) sample of 1,000 adults completed 
an online survey about their interest in an EHR mobile application. Interest in the 
application was elucidating using a 7-point Likert scale and a standard gamble 
(SG) exercise. Results: Prior to any indication of a potential privacy risk, 31% of 
consumers indicate they would be very likely to download an EHR mobile applica-
tion (rated 6 or 7 on 7-point Likert scale; 4.0 mean). Nearly half (44%) of those who 
do not expect to use the app indicate they have privacy concerns. Based on the SG, 
only 50% report they would download the mobile application if there was a 95% 
chance their data was completely secure. Expected use of the application declines 
rapidly; 39% would use it if there was a 90% chance their data was completely 
secure and 31% would use it if there was an 85% chance their data was completely 
secure. Only 3% are still interested in the application with only a 5% chance their 
data was completely secure. cOnclusiOns: There is a sizeable market for EHR 
mobile applications. Up to half of consumers report interest in using an EHR mobile 
application; and yet, there are important data concerns. Particularly given large-
scale data breaches of large organizations, it will be critical for developers to quell 
fears of potential users of a data leak.
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An AnAlysIs of germAn g-bA Added benefIt Assessment deCIsIons 
usIng tHe World HeAltH orgAnIzAtIon dAly frAmeWork
Loftus BM, Gustavsen G, Gaebler JA
Health Advances, Weston, MA, USA
Objectives: Since January 2011, the German G-BA has evaluated new drugs on 
their degree of added benefit versus a comparator therapy. We used disease-specific 
Disability Adjusted Life Years (DALYs), reported by the World Health Organization 
(WHO) as the sum of Years of Life Lost from mortality (YLL) plus Years Lost due to 
Disability (YLD), to help explain G-BA benefit assessment decisions. MethOds: 
EMA-approved drugs (January 2010-June 2015) were identified from European Public 
Assessment Reports (EPARs) and cross-referenced with the G-BA website to create 
an analysis set of drugs that have received benefit assessment ratings. Drugs with 
EMA orphan-drug designation were excluded. We defined Added Benefit (AB) as 
drugs that received G-BA ratings of “considerable”, “low”, or “unquantifiable” ben-
efit in any patient subgroup, and No Added Benefit (NAB) as drugs only receiving 
ratings of “no additional benefit” and “inferior”. Using WHO-reported German 2012 
DALYs, proportions of YLLs and YLDs for each drug’s lead indication were calculated: 
Drugs for diseases in which YLLs > 75% of the DALY were defined as High Mortality 
Drugs (HMD); drugs for all other diseases were Low Mortality Drugs (LMD). We then 
predicted the odds of receiving AB versus NAB based on this new metric. SPSS was 
used to perform Fisher’s exact test and to generate Odds Ratios (OR). Sensitivity 
analyses were performed on the %YLL threshold definition. Results: From 373 
EPARs, we identified 73 non-orphan drugs receiving G-BA benefit assessment rat-
ings, 58 of which had matched DALY data for the lead indication. Of these 58 drugs, 
35 were indicated for HMDs while 23 had LMD indications. 30 of 35 (86%) HMDs 
received an AB rating while only 4 of 23 (17%) LMDs received an AB rating (p< 0.001, 
OR: 28.6). cOnclusiOns: Our analysis suggests that in Germany there may be a 
demonstrated and predictable bias for drugs for fatal diseases.
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romAnIA’s neW HtA system: WHAt Progress HAve InnovAtIve drugs 
mAde under tHe PoInts-bAsed system so fAr?
Melck B
IHS, London, UK
Objectives: To assess the progress of a large group of innovative drugs evaluated 
recently under the HTA system introduced in Romania in 2014, which is the mecha-
nism now used to reach decisions on which new medicines are included on the 
reimbursement list. MethOds: A systematic study of the HTA decisions already 
taken by the department for health technology assessment of the Romanian drug 
agency was undertaken, to ascertain the number of medicines / indications approved 
for unconditional reimbursement (not requiring cost-volume contracts), conditional 
reimbursement (requiring cost-volume contracts) and those not qualifying for reim-
bursement. Patterns were sought and identified among those drugs / indications 
which are awarded higher and lower points scores. Results: Of the 144 HTA deci-
sions, considering only originator medicines and their indications, there have been 23 
recommendations for unconditional reimbursement, 51 recommendations for condi-
tional reimbursement, and 70 recommendations for exclusion from reimbursement. 
Among the therapeutic areas and drug types in which unconditional reimbursement 
decisions are frequent are new oral anticoagulant drugs and type-2 diabetes drugs. 
Many older originator medicines have tended to receive lower points scores, not quali-
fying for reimbursement. cOnclusiOns: The HTA points system in Romania is in its 
early stages but already some patterns are emerging from the combination of criteria 
used to accumulate points – including decisions by western European HTA bodies, 
the number of EU member states in which a drug is reimbursed, and the impact on 
the budget of the Romanian health insurer. With major legislative transformations 
underway in Romania’s pharmaceutical pricing and reimbursement system, the real 
made available to patients. The objective of this abstract is to highlight the difference 
of data requirements between the EMA and some of the main HTA bodies, and the 
subsequent outcomes in terms of access and reimbursement decisions. MethOds: 
The list of medicines under CA status was downloaded on March 16th 2015 from the 
EMA website.2 For each medicine, advice from the National Institute for Health and 
Care Excellence (NICE), Scottish Medicines Consortium (SMC), National Authority 
for Health (HAS) and Federal Joint Committee (GBA) was taken from the agencies’ 
websites.3 The HTA outcomes were measured from final recommendation in the 
UK, the medical benefit (SMR) and improvement in medical benefit (ASMR) scores 
in France and the level of additional benefit in Germany. Medicines approved 
after March 2014 (n = 3) and vaccines (n = 2) were excluded. Results: 77% of the 
selected medicines had at least one unfavourable HTA outcome (defined as no or 
restricted recommendation in the UK, SMR lower than substantial and/or ASMR V 
in France, no or unquantifiable additional benefit in Germany). 50% had a majority 
of unfavourable HTA outcomes. cOnclusiOns: Although the EMA seems to have 
accelerated patient access to selected medicines, it does not actually translate into 
patient accessibility as regulators and payers have a different perception on the 
benefits these medicines offer. Greater alignment between regulators and payers is 
needed for patients. 1Article 14(7) of Regulation (EC) No 726/2004; 2http://www.ema.
europa.eu/ema/; 3http://www.has-sante.fr/portail/jcms/r_1500918/en/les-avis-sur-
les-medicaments, http://www.english.g-ba.de/, https://www.nice.org.uk/, https://
www.scottishmedicines.org.uk/Home
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Objectives: Hospitals need a formalized system to introduce new health tech-
nologies. Hospital-based HTA (HB-HTA) units can provide relevant and timely 
information to decision makers. However, to date no comprehensive body of 
knowledge of current practices and tools exists to guide how to set up these units 
in hospitals. AdHopHTA, a European research project funded by the FP7, aims to 
gather information and knowledge and develop these tools. Therefore, our objec-
tives are to present the handbook and web-based toolkit for HB-HTA developed 
by the AdHopHTA project, which aims to guide and facilitate the setting-up and 
the daily work (e.g. assessments) of an HB-HTA unit. MethOds: AdHopHTA has 
used a multi-method approach to develop the content of the handbook and toolkit 
including 6 literature reviews, 107 face-to-face surveys, 40 case studies, 1 large-
scale survey, 1 focus group, 1 Delphi process, 1 validation workshop and several 
Steering and Advisory Committee meetings. In total 375 people from 20 differ-
ent countries have provided their input. Results: The handbook presents the 
informational needs and organizational models of HB-HTA units in Europe. It also 
describes the positive impact of HB-HTA in the adoption of new health technolo-
gies in hospitals and how to create a comprehensive HTA ecosystem through the 
interaction between national or regional HTA organizations and HB-HTA units. 15 
guiding principles for good practices in HB-HTA are also presented using current 
examples from existing HB-HTA units. The Toolkit is built based on these guiding 
principles. It consists of practical guidance grouped into four dimensions (the 
assessment process; leadership, strategy and partnerships; resources and and 
impact). It includes proposed solutions to potential problems as well as specific 
tools (e.g. AdHopHTA mini-HTA template) for each dimension. cOnclusiOns: 
The AdHopHTA Handbook and Toolkit are support instruments for designing, 
setting-up and running HB-HTA units.
PHP242
tHe CeesP eConomIC evAluAtIon: CAn ClInICAl effICACy And Cost-
effeCtIveness Co-exIst In frAnCe
Gambari J1, Beckerman R2
1CBPartners, New York, NY, USA, 2Maple Health Group, LLC, New York, NY, USA
Objectives: The Commission for Economic Evaluations and Public Health 
(Commission Evaluation Economique et de Santé Publique, (CEESP)) has been con-
ducting health economic evaluations since 2008. Due to continued economic pressure, 
as of October 2013, manufacturers are required to submit an economic evaluation to 
the CEESP under certain conditions, in addition to the Commission de Transparence’s 
existing clinical assessment. The objective of this analysis was to gain a better under-
standing of the drivers of positive and negative CEESP decisions. MethOds: All publi-
cally available CEESP decisions were retrieved from the agency’s website in April 2015. 
The CEESP evaluates submissions against the HAS’ pharmacoeconomic guidelines, in 
which areas of weakness are identified through a system of “reserves” rather than a 
strict ICER threshold. Data was extracted to determine the number of and rationale 
for minor, important, and major reserves awarded by CEESP to the manufacturer’s 
submission, as well as accepted incremental cost-effectiveness ratios. Results: 
According to HAS’s methodological guide for economic evaluations, cost-effectiveness 
should be considered alongside clinical efficacy. At the time of analysis, four CEEPS 
appraisals were publically available. 50% of submissions had ICERs above 100,000 EUR 
per QALY gained, and based on findings to date, no firm ICER threshold was apparent. 
50% of submissions were found to have minor, important, as well as major reserves. 
Our analysis revealed 5 key factors to improve the chance of a positive CEESP review: 
(1) A clearly presented analysis with a validated model structure; (2) a submission 
that satisfies the HAS guidelines; (3) a proper justification of all model inputs and 
assumptions; (4) an appropriate comparator; (5) a consideration of the “national fac-
tor”. cOnclusiOns: CEESP appraisal has only recently emerged as a market access 
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collated and analyzed descriptively. Results: The implementation of LED-guided 
drug picking significantly reduced near misses for wrong drug [7.18 ± 3.17 vs 2.71 ± 
1.36, p< 0.001] and wrong strength [3.47 ± 2.48 vs 1.82 ± 1.13, p= 0.02]. There was no 
significant difference in the frequency of picking near misses for wrong quantity 
[17.8 ± 9.88 vs 14.0 ± 4.64, p= 0.162]. Overall, there was a significant reduction in the 
frequency of total picking near misses [28.4 ± 13.2 vs 18.1 ± 5.44, p= 0.007]. Pharmacy 
staff’s acceptance towards LED-guided picking was generally positive with majority 
preferring the LED over no LED-guided drug picking. cOnclusiOns: Incorporation 
of LED into drug picking significantly decreased near misses of wrong drug and 
strength that potentially prevented costly medication errors. Pharmacy staff were 
generally receptive to LED-guided picking.
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submItted to nICe As PArt of sIngle teCHnology APPrAIsAls (stA) or 
multIPle teCHnology APPrAIsAls (mtA) In tHe lAst tHree yeArs
Srivastava K, Rajora P, Gupta S, Bisen R
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Objectives: The aim of this review was to assess the critiques highlighted by the 
ERG for SR submitted to NICE by manufacturers as part of STA or MTA. MethOds: 
ERG reports available on the NICE website were systematically searched for the 
last three years (2013-2015). The ERG comments in the documents were care-
fully assessed along with the submission documents. Emphasis was placed on 
ERG comments regarding search strategy design, electronic databases used for 
article retrieval, inclusion/exclusion criteria in SR, and reporting of SR methodol-
ogy. Results: Fourteen ERG comment documents were identified by the search 
conducted in May 2015. Ten documents were identified in 2013, three in 2014, and 
one in 2015. Comments on search strategies, such as incorrect search terms, miss-
ing terms, and wrong explosion, were made on seven submissions. Major findings 
such as chances of omission of key studies, missing intervention synonyms, and 
improper presentation of search strategies were cited in two submissions. Two sub-
missions did not search the minimum number of electronic databases indicated 
by NICE. ERG comments around SR inclusion/exclusion criteria were ambiguity in 
the study selection criteria, omission of the intervention of interest, selection of 
inappropriate follow-up duration, introduction of additional exclusion criteria at a 
later stage, exclusion of studies based on sample size, a clinically irrelevant primary 
outcome, exclusion of non-English studies even in cases of data gaps, and exclusion 
of some geographical subgroups without rationale. The write-up of SR was inad-
equate in two submissions because of ambiguity around the number of reviewers 
at each stage, unclarity around second check of extracted data, poor reporting of 
methodology, and an incorrect study selection flowchart. cOnclusiOns: The ERG 
findings demonstrate a gap in manufacturer’s search strategy design, rationale for 
inclusion/exclusion criteria, and writing-up of the SR methodology which has led 
to additional work while providing clarifications to NICE.
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Yong C, Jiang Y, Sun D, Duttagupta S
CBPartners, New York, NY, USA
Objectives: The objective of this study was to analyze the influence and develop-
ment of 13 HTA bodies in select Emerging Markets. MethOds: This study examined 
13 HTA bodies in Latin America (Argentina, Brazil, Colombia, and Mexico), Asia (Korea, 
Taiwan, China, Singapore, Malaysia, and Thailand), Africa (South Africa), Middle East 
(Saudi Arabia), as well as Central and Eastern Europe (Turkey). The countries were 
selected based on the diversity associated with the HTA evaluation process, and 
were assessed for their review timeline, influence on the pricing and reimbursement 
process, and anticipated future developments as indicated from their websites and 
other publications. Results: Among the 13 selected HTA bodies, five countries (KOR, 
TWN, BRA, TUR, and ARG) have a defined review timeline; assessment outcomes 
will generally become available within a 1-year of submission. However, a standard 
timeline has yet to be defined for the rest of the countries. Four countries (KOR, TWN, 
BRA, and MEX) have formal HTA bodies, and assessments are mandatory in the pric-
ing and reimbursement process. In other six countries (SGP, ARG, COL, THA, SAU, 
and TUR), HTA assessments may be considered in the pricing and reimbursement 
evaluation. For CHN / MYS / ZAF, although an HTA body is under development, it does 
not currently have any impact on the reimbursement decision-making. For future 
HTA developments, the focus remains on scope expansion, capability building, and 
international collaboration. cOnclusiOns: Emerging markets have developed or are 
in the process of developing HTAs for the evaluation of formulary inclusion and as a 
method of cost containment. The HTA bodies in the selected emerging markets have 
varying impact over the pricing and reimbursement process. The ones with greater 
influence tend to have a defined review timeline and an HTA body that is a formal 
authority with a mandatory and / or influential assessment.
PHP251
Assessment of Consumer lIkelIHood to AdoPt An eleCtronIC HeAltH 
reCord (eHr) mobIle APPlICAtIon And tHe ImPACt of PerCeIved rIsk of 
PrIvACy leAks
Claeys C, Tomaszewski K, Radley C, Wasserman D
KJT Group, Inc., Honeoye Falls, NY, USA
Objectives: This study was designed to understand consumer likelihood to adopt 
a mobile application designed to allow individuals to view their personal health 
record on a mobile device as a function of risk tolerance of private medical data 
leaks, including variability by various demographics. MethOds: A representative 
(U.S.) sample of 1,000 adults completed an online survey about their interest in an 
EHR mobile application. Interest in the application was elucidating using a 7-point 
Likert scale and a standard gamble (SG) exercise. The multivariate relationship 
between overall likelihood of mobile application use and SG utilities, education level, 
age, income level, and satisfaction with personal physician was assessed. Results: 
impact of the HTA system will be revealed by the number of drugs recommended 
that are subsequently placed on the reimbursement list, and with what restrictions.
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dIreCt evIdenCe versus lACk of dIreCt evIdenCe And tHe ImPACt on 
HtA ACCePtAnCe
Griffiths EA, Sheppard FR, Pathak S, Hendrich J, Martin RL, Lalli A
PAREXEL, London, UK
Objectives: Health technology assessment (HTA) agencies generally prefer the 
submission of direct evidence when appraising new interventions; however, an 
absence of head-to-head trial data is relatively common and indirect comparison 
is often required to determine relative effectiveness. To inform future submissions, 
acceptance rates across six HTA agencies were compared between submissions 
presenting direct evidence (active-comparator studies) and submissions lacking 
direct evidence. MethOds: All single HTA appraisals from 2014 for NICE (England), 
SMC (Scotland), CADTH (Canada), PBAC (Australia), IQWIG (Germany), and HAS 
(France) were included in the analysis, including resubmissions. Multiple technology 
appraisals, vaccination programmes, requests for advice, and submissions where 
the clinical evidence base was not described were excluded. The recommenda-
tion, reasoning behind the recommendation, and type of evidence presented were 
extracted. Fisher’s exact test was used to test for statistical significance. Results: 
In 2014, NICE accepted 92% (11/12) of all submissions presenting direct evidence 
versus 88% (7/8) of submissions lacking direct evidence, SMC accepted 79% (26/33) 
versus 87% (13/15), CADTH accepted 90% (9/10) versus 53% (10/19), PBAC accepted 
50% (26/52) versus 82% (14/17), IQWIG accepted 48% (13/27) versus 13% (2/15), and 
HAS accepted 97% (42/43) versus 92% (35/38). A lack of direct evidence tended to 
be acceptable in cases where hard endpoints could be compared, and in disease 
areas with small patient numbers or a lack of therapeutic alternatives. Adjusted 
indirect comparisons were generally favoured over unadjusted comparisons, where 
presented. cOnclusiOns: With the exception of IQWiG (p= 0.025), acceptance rates 
for submissions reporting direct evidence were not significantly different to rates 
for submissions lacking direct evidence for each agency, although acceptance rates 
varied across HTA agencies. Single-arm or placebo-controlled trials continue to 
be viewed as acceptable clinical evidence by most HTA agencies when such study 
designs are justifiable, and when relative efficacy can be demonstrated through 
robust indirect comparison.
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HeAltH teCHnology Assessment ArCHetyPe: ImPlICAtIon on lAunCH 
PlAnnIng And evIdenCe syntHesIs
Mazumder D1, Kapoor A1, Gwatkin N2, Medeiros C3
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Objectives: We aimed to quantitatively segment the health technology assessment 
(HTA) agencies into functional archetypes to sort countries with similar functional 
objectives and process into one group. MethOds: Through literature search, we 
developed a Likert scale comprising 77 question from 18 best practice principles, and 
6 functional domains. Each question is marked on a scale of 0-5, with higher score 
(4 or 5) indicating best practice/ease of accession and low score (0 or 1) indicating 
lack of guidance/difficulty in accession. Our scale includes the key attributes of HTA 
process, i.e. general submission process, pharmacoeconomics, pricing, and evidence 
requirements under six functional domains: transparency, process, technical, equity, 
speed and implementation. Results: We evaluated HTA guidelines and process 
of 66 HTA agencies worldwide, followed by scoring and weighted analysis. Using 
univariate analysis on total weighted score, we segregated the dataset into five 
percentiles, with definition reflecting functional objectives: 0-25% (Price Managers), 
26-50% (Formulary Managers), 51-75% (Cost Advisors), 76-90% (Value Appraisers), 
and 91-100% (Value Implementers). Characteristically, Price Managers (eg. Singapore, 
India, Hong Kong) are free pricing markets, where setting drug price is the only hur-
dle in market access. Formulary Managers (eg. US, China) control drug price based 
on budget and regulatory approval. Cost Advisors (eg. Brazil, Mexico) are emerging 
HTA agencies that use HTA to advice cost. Value Appraisers (eg. South Korea, New 
Zealand) perform HTA on regular basis, but regional requirements overcome imple-
mentation of findings to drug price and reimbursement. Value implementers (eg. 
England, Canada, Germany) are the most mature markets, with pay for performance 
measures being the primary functional objective. cOnclusiOns: Our analysis pro-
vides a new approach to quantitatively benchmark and group HTA agencies into 
archetypes based on functional objectives and local priorities. Analysis at domain 
and principle level helps mapping the similarity of requirements by each archetype, 
enabling evidence-based launch planning.
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drug PICkIng In An outPAtIent PHArmACy
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Objectives: Medication errors may occur during the drug picking process whereby 
the wrong drug, strength or quantity is picked. In May 2012, LED were installed 
and tagged to drug bins at the outpatient pharmacy in Singapore General Hospital 
with the intent to prevent these costly errors. Upon scanning a Quick Response 
(QR) code on the drug label, the LED corresponding to the drug bin will light up, 
signaling the picker to the correct drug bin. This study seeks to evaluate the safety 
impact of LED-guided drug picking and pharmacy staff’s acceptance of this sys-
tem. MethOds: The primary outcome of this study is the safety of the drug picking 
process measured in terms of the frequency of picking near misses. Near miss data 
before (January to April 2012) and after (May to August 2012) implementation of 
LED-guided drug picking were extracted electronically for statistical comparison. 
A survey was administered on pharmacy staff (n = 50) to find out their accept-
ance on drug picking with and without LED-guidance. Data from the survey were 
